Industrials
Enovis Corporation(ENOV)
Live Price
Offline$21.97
+5.37% today
1Y Change
-34.17%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $1.38B
- Revenue Growth
- +6.7%
- EPS Growth
- -39.7%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Enovis Corporation (ENOV) is a Industrials stock with a market cap of $1.38B and listed on NYSE. The stock last traded around $21.97 and down 34.2% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +6.7%, EPS growth of -39.7%, a dividend yield of 0.0%. What stands out right now is revenue +6.7%, EPS -39.7%, free cash flow +129.6% with operating margin -52.6% and ROIC -35.9%. Valuation is more restrained than many high-expectation growth names at price/sales 0.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ENOV price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Industrials peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.7% vs +6.8% peer median
Operating Margin
Below sector median
-52.6% vs +16.9% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +6.7% and EPS is at -39.7%, with operating margin around -52.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -7.0% | -5.9% | -16.5% |
2026 Feb 26, 2026 | +17.3% | +0.2% | -4.3% | -8.1% |
2025 Nov 6, 2025 | +11.9% | -1.3% | +8.6% | -4.9% |
Benchmark Edge
ENOV vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ENOV
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ENOV Max Drawdown
-41.99%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ENOV and SPY.
Company Overview
Enovis Corporation
New York Stock Exchange
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
- Leadership
- Damien McDonald
- IPO Date
- May 8, 2008
- Employees
- 7.4k
- Street Address
- 2711 Centerville Road
- Mailing
- Wilmington, DE, 19808
- Region
- Wilmington, DE, US
- Reporting Currency
- USD
- Investor Line
- 302 252 9190
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.6
- Price/Book
- 0.9
Growth
- Revenue
- +6.7%
- EPS
- -39.7%
- Free Cash Flow
- +129.6%
Profitability
- Gross Margin
- 59.8%
- Operating Margin
- -52.6%
- Net Margin
- -52.7%
- ROE
- -54.4%
- ROIC
- -35.9%
Balance Sheet
- Debt/Equity
- 0.93
- Current Ratio
- 2.02
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.